|
1
|
Mathé G, Amiel JL, Schwarzenberg L,
Schneider M, Cattan A, Schlumberger JR, Hayat M and De Vassal F:
Active immunotherapy for acute lymphoblastic leukaemia. Lancet.
1:697–699. 1969. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Carswell EA, Old LJ, Kassel RL, Green S,
Fiore N and Williamson B: An endotoxin-induced serum factor that
causes necrosis of tumors. Proc Natl Acad Sci USA. 72:3666–3670.
1975. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Old LJ, Clarke DA and Benacerraf B: Effect
of bacillus Calmette-Guérin infection on transplanted tumours in
the mouse. Nature. 184:291–292. 1959. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Redelmansidi G, Glickman MS and Bochner
BH: The mechanism of action of BCG therapy for bladder cancer-a
current perspective. Nat Rev Urol. 11:153–162. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Suriano F, Santini D, Perrone G, Amato M,
Vincenzi B, Tonini G, Muda A, Boggia S, Buscarini M and Pantano F:
Tumor associated macrophages polarization dictates the efficacy of
BCG instillation in non-muscle invasive urothelial bladder cancer.
J Exp Clin Canc Res. 32:872013. View Article : Google Scholar
|
|
6
|
De Boer EC, De Jong WH, Van Der Meijden
AP, Steerenberg PA, Witjes JA, Vegt PD, Debruyne FM and Ruitenberg
EJ: Presence of activated lymphocytes in the urine of patients with
superficial bladder cancer after intravesical immunotherapy with
bacillus Calmette-Guérin. Cancer Immunol Immun. 33:411–416. 1991.
View Article : Google Scholar
|
|
7
|
Beatty JD, Islam S, North ME, Knight SC
and Ogden CW: Urine dendritic cells: A noninvasive probe for immune
activity in bladder cancer? Bju Int. 94:1377–1383. 2014. View Article : Google Scholar
|
|
8
|
Siracusano S, Vita F, Abbate R, Ciciliato
S, Borelli V, Bernabei M and Zabucchi G: The role of granulocytes
following intravesical BCG prophylaxis. Eur Urol. 51:1589–1599.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
De Boer EC, De Jong WH, Steerenberg PA,
Aarden LA, Tetteroo E, De Groot ER, Van der Meijden AP, Vegt PD,
Debruyne FM and Ruitenberg EJ: Induction of urinary interleukin-1
(IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical
immunotherapy with bacillus Calmette-Guérin in superficial bladder
cancer. Cancer Immunol Immun. 34:306–312. 1992. View Article : Google Scholar
|
|
10
|
Böhle A, Gerdes J, Ulmer AJ, Hofstetter AG
and Flad HD: Effects of local bacillus Calmette-Guerin therapy in
patients with bladder carcinoma on immunocompetent cells of the
bladder wall. J Urol. 144:53–58. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jackson AM, Alexandroff AB, Kelly RW,
Skibinska A, Esuvaranathan K, Prescott S, Chisholm GD and James K:
Changes in urinary cytokines and soluble intercellular adhesion
molecule-1 (ICAM-1) in bladder cancer patients after bacillus
Calmette-Guérin (BCG) immunotherapy. Clin Exp Immunol. 99:369–375.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shintani Y, Sawada Y, Inagaki T, Kohjimoto
Y, Uekado Y and Shinka T: Intravesical instillation therapy with
bacillus Calmette-Guérin for superficial bladder cancer: Study of
the mechanism of bacillus Calmette-Guérin immunotherapy. Int J
Urol. 14:140–146. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jitao W, Jinchen H, Qingzuo L, Li C, Lei
S, Jianming W and Zhenli G: Androgen receptor inducing bladder
cancer progression by promoting an epithelial-mesenchymal
transition. Andrologia. 46:1128–1133. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Noguera-Ortega E, Rabanal RM,
Secanella-Fandos S, Torrents E, Luquin M and Julián E: γ Irradiated
mycobacteria enhance survival in bladder tumor bearing mice
although they are less efficacious than live mycobacteria. J Urol.
195:198–205. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Anderson KL, Smith KA, Perkin H, Hermanson
G, Anderson CG, Jolly DJ, Maki RA and Torbett BE: PU.1 and the
granulocyte- and macrophage colony-stimulating factor receptors
play distinct roles in late-stage myeloid cell differentiation.
Blood. 94:2310–2318. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tamura T, Nagamura-Inoue T, Shmeltzer Z,
Kuwata T and Ozato K: ICSBP directs bipotential myeloid progenitor
cells to differentiate into mature macrophages. Immunity.
13:155–165. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nagamura-Inoue T, Tamura T and Ozato K:
Transcription factors that regulate growth and differentiation of
myeloid cells. Int Rev Imm. 20:83–105. 2001. View Article : Google Scholar
|
|
19
|
Sharma P, Old LJ and Allison JP:
Immunotherapeutic strategies for high-risk bladder cancer. Semin
Oncol. 34:165–172. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pearl R: On the Pathological relations
between cancer and tuberculosis. Exp Biol Med. 26:73–75. 1928.
View Article : Google Scholar
|
|
21
|
Morales A, Eidinger D and Bruce AW:
Intracavitary Bacillus Calmette-Guerin in the treatment of
superficial bladder tumors. J Urol. 116:180–183. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Alexandroff A, Jackson A, Skibinska A and
James K: Production of IL-5, a classical T(H)2 cytokine, following
bacillus calmette guerin immunotherapy of bladder cancer. Int J
Oncol. 9:179–182. 1996.PubMed/NCBI
|
|
23
|
Mugiya S, Ozono S, Nagata M, Takayama T,
Ito T, Maruyama S, Hadano S and Nagae H: Long-term outcome of a
low-dose intravesical Bacillus Calmette-Guerin therapy for
carcinoma in situ of the bladder: Results after six successive
instillations of 40 mg BCG. Jpn J Clin Oncol. 35:395–399. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ye W, Jiang Z, Li GX, Xiao Y, Lin S, Lai
Y, Wang S, Li B, Jia B, Li Y, et al: Quantitative evaluation of the
immunodeficiency of a mouse strain by tumor engraftments. J Hematol
Oncol. 8:592015. View Article : Google Scholar : PubMed/NCBI
|
